New Antibiotics for Treating Infections Caused by Multidrug-Resistant Bacteria

Introduction Antibiotic-resistant bacteria are a growing global threat, causing longer hospital stays, higher costs, and increased mortality. The rise of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacteria—such as…

Continue ReadingNew Antibiotics for Treating Infections Caused by Multidrug-Resistant Bacteria

Oral care medications for the prevention and treatment of ventilator-associated pneumonia in intensive care unit

Introduction Ventilator-associated pneumonia (VAP) is a common and serious infection in ICU patients who undergo invasive mechanical ventilation for more than 48 hours. It is caused by various microorganisms, including…

Continue ReadingOral care medications for the prevention and treatment of ventilator-associated pneumonia in intensive care unit

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics

Introduction The rise of antimicrobial resistance, especially among Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor (BL/BLI) combinations. Recently approved agents—cefepime/enmetazobactam, aztreonam/avibactam, and sulbactam/durlobactam—target resistant pathogens like…

Continue ReadingNew β-Lactam/β-Lactamase Inhibitor Combination Antibiotics

Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Introduction (Article introduction authored by INCA Editorial Team) Acinetobacter baumannii complex (ABC), particularly its carbapenem-resistant strains (CRAB), presents a significant challenge due to its high resistance to antibiotics and its…

Continue ReadingAcinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Meeting the Therapeutic Challenges of Emergent and Rare Invasive Fungal Diseases Through Novel Clinical Trial Designs

Introduction (Article introduction authored by ICU Editorial Team) Treatments for rare and emerging invasive fungal diseases (IFDs) are urgently needed. Diseases such as mucormycosis, hyalohyphomycosis, and phaeohyphomycosis occur less frequently…

Continue ReadingMeeting the Therapeutic Challenges of Emergent and Rare Invasive Fungal Diseases Through Novel Clinical Trial Designs

New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections

Introduction (Article introduction authored by ICU Editorial Team) Nosocomial CNS infections with carbapenem- and colistin-resistant Gram-negative and vancomycin-resistant Gram-positive bacteria present a growing therapeutic challenge. This review examines the pharmacokinetics,…

Continue ReadingNew Antibiotics for the Treatment of Nosocomial Central Nervous System Infections